Preservation of endothelium-dependent vascular relaxation in cholesterol-fed mice by the chronic administration of prazosin or pravastatin

Japanese Journal of Pharmacology

Volumn 70, Issue 2, 1996, Pages 149-156

  Kamata, Katsuo ^a   Kojima, Satoshi ^a   Sugiura, Makoto ^a   Kasuya, Yutaka ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Endothelium; Low density lipoprotein (LDL); Lysoghosphatidylcholine (LPC); Pravastatin; Prazosin

Indexed keywords

ACETYLCHOLINE; ARGININE; ARGININE DERIVATIVE; CALCIMYCIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDOMETACIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; NITROPRUSSIDE SODIUM; PRAVASTATIN; PRAZOSIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HYPERCHOLESTEROLEMIA; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION;

EID: 0030005888     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.70.149     Document Type: Article

References (42)

1. Verbeuren TJ, Jordens FH, Zonnekeyn LL, Vanhove CE, Coene MC and Herman AG: Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res 58, 552-564 (1986)
2. Bossaller C, Habib GB, Yamamoto H, Williams C, Wells W and Henry PD: Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 3′,5′-monophosphate formation in the atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 79, 170-174 (1987)
3. Jayakody L, Senarine M, Thomoson A and Kappagoda T: Endothelium-dependent relaxation in experimental atherosclerosis in the rabbit. Circ Res 60, 251-264 (1987)
4. Freiman RC, Mitchell GG, Heistad DD, Armstrong MI and Harrison DG: Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 58, 783-789 (1986)
5. Yamamoto Y, Tomoike H, Egashira K and Nakamura M: Attenuation of endothelium-related relaxation and enhanced responsiveness of vascular smooth muscle to histamine in spastic coronary arterial segments from miniature pigs. Circ Res 61, 772-778 (1987)
6. Shimokawa H and Vanhoutte PM: Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res 64, 900-914 (1989)
7. Forstermann U, Mugge A, Alheid U, Haverich A and Frolich JC: Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 62, 185-190 (1988)
8. Lunder PI, Selwyn AP, Shook TI, Wayne RR and Mudge GH: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315, 1046-1050 (1986)
9. Quinn MT, Parthasarathy S, Fong LG and Steinberg D: Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 84, 2995-2998 (1987)
10. Berliner JA, Territo MC, Sevanian A, Ramins S, Kim JAi, Bamshad B, Esterson M and Fogelman AM: Minimally modified low density lipoprotein stimulates monocyte endothelial interaction. J Clin Invest 85, 1260-1267 (1990)
11. Steinbrecher UP, Parthasarrathy S, Leake DS, Witztum JL and Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc Natl Acad Sci USA 81, 3883-3887 (1984)
12. Kugiyama K, Kerns SA, Morrisett JD, Roberts R and Henry PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344, 160-162 (1990)
13. Witztum JL and Steinberg D: Role of oxidized low density lipoprotein in atherosclerosis. J Clin Invest 88, 1785-1792 (1991)
14. Yokoyama M, Hirata K, Miyake R, Akita H, Ishikawa Y and Fukuzaki H: Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low-density lipoprotein. Biochem Biophys Res Commun 168, 301-308 (1990)
15. Kugiyama K, Ohgushi M, Sugiyama S, Murohara T, Fukunaga K, Miyamoto E and Yasue H: Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res 71, 1422-1428 (1992)
16. Sugiyama S, Kugiyama K, Ohgushi M, Fujimoto K and Yasue H: Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Role of protein kinase C. Circ Res 74, 565-575 (1994)
17. Flavahan NA: Lysophosphatidylcholine modifies G protein-dependent signaling in porcine endothelial cells. Am J Physiol 264, H722-H727 (1993)
18. Lee T-J: Synthesis, SARs and therapeutic potential of HMG-CoA redcutase inhibitors. Trends Pharmacol Sci 8, 442-446 (1987)
19. Saxenhofer H, Weidmann P, Riesen WF, Beretta-Piccoli C, Fragiacomo C, Wunderlin R and Noseda G: Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemaia type II. Eur J Clin Pharmacol 39, 101-105 (1990)
20. Hunninghake DB, Knopp RH, Schonfeld G, Goldberg AC, Brown WV, Schaefer EJ, Margolis S, Dobs AS, Mellies MJ, Insull W Jr and Stein EA: Efficacy and safety of pravastatin in patient with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis 85, 81-89 (1990)
21. Krupp MN, Hoover KW and Valentine JJ: Effects of doxazosin and other antihypertensive on serum lipid levels and lipoprotein lipase in the C57BR/cdj mouse. J Cardiovasc Pharmacol 13, Supp 2, S11-S19 (1989)
22. Pool JL: Plasma lipid lowering effects of doxazosin, a new selective alphal, adrenergic inhibitor for systemic hypertension. Am J Cardiol 59, 46G-50G (1987)
23. Frick MH, Cox DA, Himanen P, Himanen P, Huttunen M, Pitkajarvi T, Porsti P, Poyhonen L, Pyykonen M-L, Reinikainen P, Saimeia P and Saraste M: Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension. Am J Cardiol 59, 61G-67G (1987)
24. Grimm RH: Thiazide diuretics and selective alpha blockers: comparison of use in antihypertensive therapy, including possible differences in coronary heart disease risk reduction. Am J Med 82, 26-29 (1987)
25. Graham RM: Selective alpha-1-adrenergic blockade, lipids, and coronary heart disease risk: consideration in the treatment of essential hypertension. Am J Med 87, 53S-56S (1989)
26. Jacob BG, Richter WO and Schwandt P: Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patient with severe primary hypercholesterolemia. J Cardiovasc Pharmacol 22, 396-400 (1993)
27. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC and Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Eng J Med 332, 481-487 (1995)
28. Ross R: The pathogenesis of atherosclerosis: an update. N Eng J Med 314, 488-500 (1986)
29. Yasue H, Matsuyama K, Matsuyama K, Okumura K, Morigami Y and Ogawa H: Response of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment: possible role of early coronary atherosclerosis. Circulation 81, 482-490 (1990)
30. Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S and Henry PD: Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 79, 170-174 (1987)
31. Steinberg UP, Parthasarathy S, Leake DS, Witzum JL and Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81, 3883-3887 (1984)
32. Kugiyama K and Henry PD: Transfer of lysophosphatidylcholine from oxidized LDL to endothelial cells impairs endothelium-dependent arterial relaxation. J Am Coll Cardiol 15, 12A, Abstract (1990)
33. Ohgushi M, Kugiyama K, Fukunaga K, Murohara T, Sugiyama S and Miyamoto E: Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified low-density lipoprotein. Arterioscler Thromb 13, 1525-1532 (1993)
34. 2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci USA 82, 3000-3004 (1985)
35. Portman OW and Alexander M: Lysophosphatidylcholine concentrations and metabolism aortic intima plus inner media: effect of nutritionally induced atherosclerosis. J Lipid Res 10, 158-165 (1969)
36. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL and Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84, 1086-1095 (1989)
37. Weinheimer G, Wagner B and Osswald H: Interaction of phorbol esters with endothelium-dependent vascular smooth muscle relaxation. Eur J Pharmacol 130, 319-322 (1986)
38. Cherry PD and Gills CN: Antagonism of acetylcholine-mediated relaxation of rabbit pulmonary arteries by phorbol myristate acetate. J Pharmacol Exp Ther 247, 542-546 (1988)
39. Rubanyi GM, Desiderio D, Luisi A, Johns A and Sybertz EJ: Phorbol dibutyrate inhibits release and action of endothelium-derived relaxing factor(s) in canine blood vessels. J Pharmacol Exp Ther 249, 858-863 (1989)
40. Morrison KJ and Pollock D: Impairment of relaxations to acetylcholine and nitric oxide by a phorbol ester in rat isolated aorta. Br J Pharmacol 101, 432-436 (1990)
41. Flavahan NA, Shimokawa H and Vanhoutte PM: Inhibition of endothelium-dependent relaxations by phorbol myristate acetate in canine coronary arteries: role of a pertussis toxin-sensitive G-protein. J Pharmacol Exp Ther 256, 50-55 (1991)
42. Kamata K, Chikada S, Umeda F and Kasuya Y: Effects of phorbol ester (PMA) on vasodilation induced by endothelium-dependent or endothelium-independent vasodilators in the mesenteric arterial bed. J Cardiovasc Pharmacol 26, 645-652 (1995)